Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06680661 · ClinicalTrials.gov registry record · Phase 2
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
A Phase 2 study of Lymphoma and Myelodysplastic Syndromes, sponsored by Leland Metheny.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06680661: Recruiting Phase 2 study of Lymphoma and Myelodysplastic Syndromes, sponsored by Leland Metheny.
NCT06680661 is a Phase 2 study of Lymphoma and Myelodysplastic Syndromes that is actively recruiting participants, run by Leland Metheny. The registered enrollment target is 20 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06680661, a Phase 2 study of Lymphoma and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Leland Metheny.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT. Participants will: * Partake in exams, tests, and procedures as part of usual cancer care. * Partake in conditioning, which is the treatment that is given before a transplant. * Have a cord blood transplant. * Partake in radiation following the transplant.
Primary Outcome
To assess severe aGVHD (grade III-IV acute GVHD) free survival (SGFS) at T+180.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Thiotepa
- RADIATION Total Body Irradiation
- BIOLOGICAL Double Umbilical Cord Transplant
Study Locations (1)
Ohio
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 2 |
What NCT06680661 shows while recruiting
NCT06680661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower).
The record links to 8 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06680661 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06680661 about?
NCT06680661 is a clinical study titled "ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis". The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention...
What is the current status of trial NCT06680661?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-02-25. Estimated completion is 2028-10-31.
What conditions does trial NCT06680661 study?
This clinical trial studies the following conditions: Lymphoma, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT06680661?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Thiotepa (DRUG), Total Body Irradiation (RADIATION), Double Umbilical Cord Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT06680661?
This trial is sponsored by Leland Metheny, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06680661 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06680661's enrollment target sits among peer trials
20 246th of 299 higher than 49 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI